Trials / Completed
CompletedNCT00889486
Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Tranzyme, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TZP-102 | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2009-04-29
- Last updated
- 2012-12-11
Locations
23 sites across 6 countries: United States, Denmark, Norway, Poland, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00889486. Inclusion in this directory is not an endorsement.